EN DE
STOCK COMPARISON

Sino Tactful Co vs Fredun Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Sino Tactful Co (5481) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Sino Tactful Co trades at TWD 19.65 versus a fair value of TWD 9.03 (-54%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
Sino Tactful Co
5481.TWO · TWD · Information Technology
-54%
upside to fair value
overvalued
PriceTWD 19.65
Fair ValueTWD 9.03
Quality45/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+77%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,155
Quality33/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Sino Tactful CoFredun Pharmaceuticals
Valuation
P/E (TTM)42.2×
0.46×P/S (TTM)2.23×
P/B5.03×
EV/EBITDA15.5×
Dividend yield0.0%
Dividend per share₹0.70
Profitability
-45%Net margin5%
-33%Operating margin12%
-4%Return on equity16%
-2%Return on assets9%
Growth
-9%Revenue growth (YoY)27%
1.1%Avg. growth/yr (3Y)32.2%
-0.9%Avg. growth/yr (5Y)36.9%
Balance & size
0.19×Debt / equity0.20×
$43MMarket cap$149M
weakGrowth qualityexpensive

Fredun Pharmaceuticals leads: 2 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Sino Tactful Coof which business quality 44 · market factors 37 Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
4
48
Quality GrowthAre margins and returns improving?
25
73
CashflowEarnings quality: real cash, not paper profit
0
5
Fin. StrengthBalance sheet, leverage, solvency risk
79
57
InvestmentDisciplined investing over empire-building
100
16
Low VolatilityCalm price path (market factor)
72
43
MomentumPrice trend over the last 3–12 months (market factor)
25
39
52W MomentumDistance to the 52-week high (market factor)
19
54
Net IssuanceBuybacks instead of dilution
90
7

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Sino Tactful Co

Dividend DiscountTWD 8.26
Asset-BasedTWD 11.98

3 of 3 models see the stock below the current price.

Fredun Pharmaceuticals

Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535

5 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Sino Tactful Co
Bear TWD 5.01Fair Value TWD 9.03Bull TWD 12.43
TWD 19.65 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹1,218 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Sino Tactful Co · Information Technology

Quality score45 · below median
Fair value upside-54% · below median

Fredun Pharmaceuticals · Healthcare

Quality score33 · bottom 25%
Fair value upside+77% · Top 25%

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Sino Tactful Co trades at TWD 19.65 versus a fair value of TWD 9.03 (-54%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).

Sino Tactful Co has the higher quality score (45/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.